Although anti-angiogenic drugs are effective, cancer patients treated with VEGFA/VEGFR2 inhibitors are liable to develop resistance likely due to cancer cells finding alternative means to drive tumour-associated angiogenesis (non-VEGFR pathway-driven angiogenesis) [7,8]. The gene discussed is KDR; the disease is cancer.